Pirin downregulation is a feature of AML and leads to impairment of terminal myeloid differentiation

Leukemia

Volumn 24, Issue 2, 2010, Pages 429-437

  Licciulli, S ^a   Cambiaghi, V ^a   Scafetta, G ^a   Gruszka, A M ^a   Alcalay, M ^a,b  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Acute myeloid leukemia; Myeloid differentiation; Pirin; Transcription

Indexed keywords

CD34 ANTIGEN; HOMEOBOX A PROTEIN; HOMEODOMAIN PROTEIN; ONCOPROTEIN; PIRIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ARTICLE; BONE MARROW CELL; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL FUNCTION; CELL LINEAGE; CELL MATURATION; CONTROLLED STUDY; CYTOGENETICS; DOWN REGULATION; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION PROFILING; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; KARYOTYPE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RNA EXTRACTION; TRANSCRIPTION REGULATION; UPREGULATION;

EID: 76749149998     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2009.247     Document Type: Article

References (27)

1. Rosenbauer F, Tenen DG. Transcription factors in myeloid development: balancing differentiation with transformation. Nat Rev Immunol 2007; 7: 105-117.
2. Look AT. Oncogenic transcription factors in the human acute leukemias. Science 1997; 278: 1059-1064.
3. Alcalay M, Meani N, Gelmetti V, Fantozzi A, Fagioli M, Orleth A et al. Acute myeloid leukemia fusion proteins deregulate genes involved in stem cell maintenance and DNA repair. J Clin Invest 2003; 112: 1751-1761.
4. Wendler WM, Kremmer E, Forster R, Winnacker EL. Identification of pirin, a novel highly conserved nuclear protein. J Biol Chem 1997; 272: 8482-8489.
5. Dechend R, Hirano F, Lehmann K, Heissmeyer V, Ansieau S, Wulczyn FG et al. The Bcl-3 oncoprotein acts as a bridging factor between NF-kappaB/Rel and nuclear co-regulators. Oncogene 1999; 18: 3316-3323.
6. Baldwin Jr AS. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 1996; 14: 649-683.
7. Pang H, Bartlam M, Zeng Q, Miyatake H, Hisano T, Miki K et al. Crystal structure of human pirin: an iron-binding nuclear protein and transcription cofactor. J Biol Chem 2004; 279: 1491-1498.
8. Adams M, Jia Z. Structural and biochemical analysis reveal pirins to possess quercetinase activity. J Biol Chem 2005; 280: 28675-28682.
9. Gelbman BD, Heguy A, O'Connor TP, Zabner J, Crystal RG. Upregulation of pirin expression by chronic cigarette smoking is associated with bronchial epithelial cell apoptosis. Respir Res 2007; 8: 10.
10. Orzaez D, de Jong AJ, Woltering EJ. A tomato homologue of the human protein PIRIN is induced during programmed cell death. Plant Mol Biol 2001; 46: 459-468.
11. Hihara Y, Muramatsu M, Nakamura K, Sonoike K. A cyanobacterial gene encoding an ortholog of Pirin is induced under stress conditions. FEBS Lett 2004; 574: 101-105.
12. Rubinson DA, Dillon CP, Kwiatkowski AV, Sievers C, Yang L, Kopinja J et al. A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat Genet 2003; 33: 401-406.
13. Finocchiaro G, Parise P, Minardi SP, Alcalay M, Muller H. GenePicker: replicate analysis of Affymetrix gene expression microarrays. Bioinformatics 2004; 20: 3670-3672.
14. Gardini A, Cesaroni M, Luzi L, Okumura AJ, Biggs JR, Minardi SP et al. AML1/ETO oncoprotein is directed to AML1 binding regions and co-localizes with AML1 and HEB on its targets. PLoS Genet 2008; 4: e1000275.
15. Viale A, De Franco F, Orleth A, Cambiaghi V, Giuliani V, Bossi D et al. Cell-cycle restriction limits DNA damage and maintains self-renewal of leukaemia stem cells. Nature 2009; 457: 51-56.
16. Rigby WF, Shen L, Ball ED, Guyre PM, Fanger MW. Differentiation of a human monocytic cell line by 1,25-dihydroxyvitamin D3 (calcitriol): a morphologic, phenotypic, and functional analysis. Blood 1984; 64: 1110-1115.
17. Testa U, Masciulli R, Tritarelli E, Pustorino R, Mariani G, Martucci R et al. Transforming growth factor-beta potentiates vitamin D3-induced terminal monocytic differentiation of human leukemic cell lines. J Immunol 1993; 150: 2418-2430.
18. Meani N, Minardi S, Licciulli S, Gelmetti V, Coco FL, Nervi C et al. Molecular signature of retinoic acid treatment in acute promye-locytic leukemia. Oncogene 2005; 24: 3358-3368.
19. Chen Y, Haviernik P, Bunting KD, Yang YC. Cited2 is required for normal hematopoiesis in the murine fetal liver. Blood 2007; 110: 2889-2898.
20. Murray LJ, Bruno E, Uchida N, Hoffman R, Nayar R, Yeo EL et al. CD109 is expressed on a subpopulation of CD34+ cells enriched in hematopoietic stem and progenitor cells. Exp Hematol 1999; 27: 1282-1294.
21. Boyd KE, Xiao YY, Fan K, Poholek A, Copeland NG, Jenkins NA et al. Sox4 cooperates with Evi1 in AKXD-23 myeloid tumors via transactivation of proviral LTR. Blood 2006; 107: 733-741.
22. Abramovich C, Humphries RK. Hox regulation of normal and leukemic hematopoietic stem cells. Curr Opin Hematol 2005; 12: 210-216.
23. Eklund EA. The role of HOX genes in malignant myeloid disease. Curr Opin Hematol 2007; 14: 85-89.
24. Guzman ML, Neering SJ, Upchurch D, Grimes B, Howard DS, Rizzieri DA et al. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 2001; 98: 2301-2307.
25. Braun T, Carvalho G, Coquelle A, Vozenin MC, Lepelley P, Hirsch F et al. NF-kappaB constitutes a potential therapeutic target in high-risk myelodysplastic syndrome. Blood 2006; 107: 1156-1165.
26. Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005; 352: 254-266. (Pubitemid 40110814)
27. Cilloni D, Messa F, Rosso V, Arruga F, Defilippi I, Carturan S et al. Increase sensitivity to chemotherapeutical agents and cytoplasmatic interaction between NPM leukemic mutant and NF-kappaB in AML carrying NPM1 mutations. Leukemia 2008; 22: 1234-1240.